Výsledky vyhledávání

Akademický článek

Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study.

Autor: Bashorun AO; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Kotei L; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Jawla O; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Jallow AF; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Saidy AJ; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Kinteh MA; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Kujabi A; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Jobarteh T; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Kanu FJ; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Donkor SA; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Ezeani E; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Fofana S; Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia., Njie M; Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia., Ceesay L; Expanded Programme on Immunization, Ministry of Health, Government of The Gambia, Kotu, The Gambia., Jafri B; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Williams A; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Jeffries D; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Kotanmi B; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia., Mainou BA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Ooko M; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Clarke E; MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia. Electronic address: ed.clarke@lshtm.ac.uk.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Apr; Vol. 24 (4), pp. 417-426. Date of Electronic Publication: 2024 Jan 15.

Zobrazit plný text záznamu

Akademický článek

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

Autor: Ochoge M; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Futa AC; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Umesi A; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Affleck L; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Kotei L; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Daffeh B; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Saidy-Jah E; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Njie A; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Oyadiran O; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Edem B; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Jallow M; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Jallow E; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Donkor SA; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia., Tritama E; Research and Development Division, PT Bio Farma, Bandung, Indonesia., Abid T; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Jones KAV; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Mainou BA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Konz JO; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Fix A; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Gast C; Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA., Clarke E; MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia. Electronic address: ed.clarke@lshtm.ac.uk.

Publikováno v: Lancet (London, England) [Lancet] 2024 Mar 23; Vol. 403 (10432), pp. 1164-1175. Date of Electronic Publication: 2024 Feb 22.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání